Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer

Background and objective Erlotinib is a small molecular inhibitor of tyrosine kinase. One study has confirmed that it can prolong the median progression-free survival time (PFS), and can improve the one-year survival rate of patients with advanced non-small cell lung cancer. The aim of this trial is...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Liyan XU, Yuhua WU, Mingzhi LI, Heling SHI, Qiyi MENG, Zan LIU, Wei WU, Zhe LIU, Junfang TANG, Yunzhong ZHU
स्वरूप:	Artigo
भाषा:	Chinês
प्रकाशित:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-12-01
श्रृंखला:	Chinese Journal of Lung Cancer
विषय:	Erlotinib Lung neoplasms Targeted therapy Therapeutic effect Prognosis
ऑनलाइन पहुंच:	http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.10&path[]=1234
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!